Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

Featured Article

News
Immune-Related Adverse Events With ICIs Linked to Improved Survival in Metastatic NSCLC
12/09/2024
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
Real-World Data Reveal Effectiveness of Systemic Therapies for BRAF Mutation-Positive NSCLC
03/17/2023
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the...
03/17/2023
First Report Managed Care
News
PD-1 Inhibitors Improve Survival in Patients With Advanced EGFR-Mutant NSCLC After TKI Resistance
03/10/2023
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the...
03/10/2023
First Report Managed Care
News
Combination Therapy Significantly Improves PFS in Patients With NSCLC With High Tumor Mutational Burden
02/15/2023
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant...
02/15/2023
First Report Managed Care
News
Robotic Lobectomy Feasible for Older Adults With NSCLC, Analysis Finds
01/27/2023
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the...
01/27/2023
First Report Managed Care
Headshot of Nasser Altorki, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Shows Disease-free Survival Benefit in Patients With NSCLC
11/09/2021
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of...
11/09/2021
First Report Managed Care
Headshot of Alex Spira, Virginia Cancer Specialists Research Institute, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Options and Unmet Need in Non-small Cell Lung Cancer
10/08/2021
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP,...
10/08/2021
First Report Managed Care

Newsfeed

News
Immune-Related Adverse Events With ICIs Linked to Improved Survival in Metastatic NSCLC
12/09/2024
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
Amivantamab–Lazertinib Extends Progression-Free Survival in Untreated EGFR-Mutated NSCLC
10/11/2024
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
Family History of Cancer Impacts Survival and Treatment Outcomes in Patients With NSCLC
10/11/2024
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
News
Challenges and Emerging Strategies in Overcoming Resistance in EGFR-Mutant NSCLC
09/10/2024
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
Real-World Data Reveal Effectiveness of Systemic Therapies for BRAF Mutation-Positive NSCLC
03/17/2023
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the role of co-mutations on response to both dual-targeted BRAF/MEK inhibition and ICI-based regimens may be important to treatment selection and optimization of patient outcome," authors advised.
"Future studies to clarify the...
03/17/2023
First Report Managed Care
News
PD-1 Inhibitors Improve Survival in Patients With Advanced EGFR-Mutant NSCLC After TKI Resistance
03/10/2023
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the efficacy and safety of PD-1 inhibitors for patients with non-small cell lung cancer after treatment with tyrosine kinase inhibitors failed.
A real-world study tested the...
03/10/2023
First Report Managed Care
News
Combination Therapy Significantly Improves PFS in Patients With NSCLC With High Tumor Mutational Burden
02/15/2023
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant monoclonal antibody therapy significantly improved outcomes in patients with locally advanced non-small cell lung cancer with high tumor mutational burden.
Chemoradiation and adjuvant...
02/15/2023
First Report Managed Care
News
Robotic Lobectomy Feasible for Older Adults With NSCLC, Analysis Finds
01/27/2023
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the postoperative outcomes of patients over 75 years of age who underwent a robotic-assisted lobectomy to treat non-small cell lung cancer.
Researchers studied the...
01/27/2023
First Report Managed Care
News
Checkpoint Inhibitors To Play Major Role in Treatment of NSCLC
12/15/2017
A recent study in The Ochsner Journal examined the role of checkpoint inhibition in non–small cell lung cancer treatment. 
A recent study in The Ochsner Journal examined the role of checkpoint inhibition in non–small cell lung cancer treatment. 
A recent study in The Ochsner...
12/15/2017
First Report Managed Care
News
Recent Research Reports New Treatment Options for NSCLC
11/21/2017
Recent research, reported in The New England Journal of Medicine, showed that Tagrisso improved outcomes among non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor.
Recent research, reported in The New England Journal of Medicine, showed that Tagrisso improved outcomes among non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor.
Recent research, reported in The...
11/21/2017
First Report Managed Care
News
Patient-Reported Outcomes Drive Value-Based Care in Multiple Sclerosis
01/13/2025
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in Journal of Managed Care & Specialty Pharmacy explored multiple sclerosis (MS) as a compelling therapeutic area for outcomes-based agreements (OBAs) by assessing the use of patient-reported disability progression to...
A recent study published in...
01/13/2025
First Report Managed Care
News
Study Highlights the Substantial Economic and Health Care Burden of Vitiligo
01/13/2025
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US...
01/13/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
News
COVID-19 Infection Linked to Increased Risk of Skin Conditions
01/08/2025
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that COVID-19 infection significantly increases the risk of developing skin conditions such as vitiligo, chronic urticaria, alopecia areata, and herpes zoster.
A recent study found that...
01/08/2025
First Report Managed Care
News
Provider Perceptions of Biosimilar Use in Oncology Networks
01/03/2025
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the...
01/03/2025
First Report Managed Care
News
Study Suggests Cognitive Impairment More Likely With Late-Onset Multiple Sclerosis
12/19/2024
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset multiple sclerosis (MS) performed worse on most classic and social cognitive domains than patients with adult-onset MS after accounting for patient age and disease duration.
Patients with late-onset...
12/19/2024
First Report Managed Care
News
Evaluating Long-Term Cost Benefits of Etranacogene Dezaparvovec in Hemophilia B Management
12/19/2024
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of Managed Care and Specialty Pharmacy evaluated the budgetary implications of introducing etranacogene dezaparvovec, a novel gene therapy for hemophilia B, into a US commercial health plan.
A study published in Journal of...
12/19/2024
First Report Managed Care
News
Financial Hardships Associated With Long COVID Across Income and Education Levels
12/19/2024
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health Services Research analyzing data from the 2022 Behavioral Risk Factor Surveillance System (BRFSS) has revealed a significant association between long COVID and financial hardships.
A study published in Health...
12/19/2024
First Report Managed Care
News
Oncology Biosimilars Offer Cost-Efficient Solutions for Sustainable Health Care
12/19/2024
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have emerged as a cost-effective and affordable alternative to their reference biologics.
Oncology biosimilars have...
12/19/2024
First Report Managed Care
News
Global Oncology Biosimilars Market to Surge to $35.79 Billion by 2034
12/19/2024
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars market is set to experience remarkable growth, with its value projected to soar from $6.50 billion in 2024 to $35.79 billion by 2034, at an impressive CAGR of 18.6%.
The global oncology biosimilars...
12/19/2024
First Report Managed Care

Insights

Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Headshot of Nasser Altorki, MD, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Shows Disease-free Survival Benefit in Patients With NSCLC
11/09/2021
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of thoracic surgery, New York Presbyterian-Weill Cornell Medicine, discusses the findings from the IMpower010 study, in which adjuvant atezolizumab resulted in a disease-free survival benefit that was superior to...
Nasser Altorki, MD, chief of...
11/09/2021
First Report Managed Care
Headshot of Alex Spira, Virginia Cancer Specialists Research Institute, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Treatment Options and Unmet Need in Non-small Cell Lung Cancer
10/08/2021
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, medical director at US Oncology Network, provides an overview of currently available treatment options in non-small cell lung cancer, and describes the...
Alex Spira, MD, PhD, FACP,...
10/08/2021
First Report Managed Care
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
Videos
Improving Survival Rates Among Patients With NSCLC Using New, Effective Treatment Strategy
06/18/2020
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign professor of medicine and professor of pharmacology, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the results of the ADAURA study that examined the use of Tagrisso...
Roy S Herbst, MD, PhD, ensign...
06/18/2020
First Report Managed Care
Formoso Headshot
Videos
Minimally Invasive Solutions for Lumbar Disc Herniation
01/07/2025
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Ferdinand...
01/07/2025
First Report Managed Care
Kolodziej Headshot
Videos
Navigating Biosimilar Adoption: Lessons from Global Markets and Clinical Practices
12/20/2024
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael...
12/20/2024
First Report Managed Care
Mike Kolodziej, MD
Videos
Exploring Biosimilar Adoption and Policy Impacts in Oncology
12/18/2024
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
In this interview, Michael...
12/18/2024
First Report Managed Care
Robbins
Podcasts
Improving Access to CGRP Therapies for Effective Migraine Treatment
12/12/2024
Explore the challenges patients face in accessing CGRP therapies for migraines, strategies to streamline treatment effectiveness, and the crucial role of health care providers in navigating access barriers and aligning clinical guidelines...
Explore the challenges patients face in accessing CGRP therapies for migraines, strategies to streamline treatment effectiveness, and the crucial role of health care providers in navigating access barriers and aligning clinical guidelines...
Explore the challenges patients...
12/12/2024
First Report Managed Care
Hennessy Headshot
Videos
Navigating Biosimilar Integration: Cost Savings, Coverage, and Future Strategies for Payers
12/10/2024
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
John Hennessy, MBA, discusses...
12/10/2024
First Report Managed Care
LMW
Podcasts
Understanding Early CGRP Therapy Initiation in Migraine Treatment
11/22/2024
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements in migraine research, treatment options, cost-effectiveness, and the role of technology in managing migraines in this informative episode.
Explore the latest advancements...
11/22/2024
First Report Managed Care
Ed
Podcasts
Improving Adherence With Long-Acting Antiretroviral Therapy for HIV
11/15/2024
Join our in-depth discussion about the challenges of HIV treatment, the importance of adherence to antiretroviral therapy, and how long-acting ART can improve treatment outcomes.
Join our in-depth discussion about the challenges of HIV treatment, the importance of adherence to antiretroviral therapy, and how long-acting ART can improve treatment outcomes.
Join our in-depth discussion...
11/15/2024
First Report Managed Care
Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use